<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01641406</url>
  </required_header>
  <id_info>
    <org_study_id>NAC CCAM 11-01</org_study_id>
    <nct_id>NCT01641406</nct_id>
    <nct_alias>NCT01330212</nct_alias>
  </id_info>
  <brief_title>&quot;Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer&quot;</brief_title>
  <acronym>NACprotocol</acronym>
  <official_title>&quot;Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auxilio Mutuo Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Auxilio Mutuo Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a novel neoadjuvant regimen for invasive breast&#xD;
      carcinoma by using the MD Anderson residual cancer burden score.To prospectively evaluate the&#xD;
      utility of the PET scan to guide the neoadjuvant treatment and the utility of the Oncotype&#xD;
      test as a stratifier for treatment decisons in ER+/Her2- patients. To evaluate the clinical&#xD;
      anti-tumor activity of neoadjuvant hormonal therapy in ER+/Her2 negative patients. To&#xD;
      evaluate the prognostic factors associated associated with pathological response as measured&#xD;
      by the residual cancer burden tool.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment propose of TEC-NAX for the triple negatives and for the Her2+ cases. For the&#xD;
      Er+/Her2- cases, we propose to use the PET scan to guide therapy after the first course of&#xD;
      TEC. Those who drop in SUV≤5%, will have their treatment modified by using the Oncotype test.&#xD;
      Those Her2 negative patients whose response to the first 4 courses of induction TEC is less&#xD;
      than a complete remission, will have their tretment changed to a second line regimen,&#xD;
      Navelbine-Avastin-Xeloda(NAX), with the intention of capturing a better response prior to&#xD;
      surgery. Those who are Her2+ will initially also receive TEC but subsequent therapy will&#xD;
      include Trastuzumab(Herceptin) whether thet respond wellor not to TEC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to obtain a RCB rate of 0-1 in at least 66%</measure>
    <time_frame>2 years</time_frame>
    <description>The primary objective is to raise the RCB rate of 0-1 to ≥40%. the startegy of using Oncotype test to guide NAC therapy will be considered encouraging for future testing if we are able to achieve this goal.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Infiltrating Duct and Lobular Carcinoma In Situ</condition>
  <condition>Invasive Lobular Breast Carcinoma</condition>
  <condition>Inflammatory Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>ER- (Triple Neg. and ER- PR+ Her 2 -)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental chemotherapy using neoadjuvant approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Her 2 +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental chemotherapy using neoadjuvant approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ER + (ER+ PR+ Her 2- / ER+ PR- Her 2 -)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental chemotherapy using neoadjuvant approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab</intervention_name>
    <description>ER-(Triple Negative and ER-PR+Her-2-):Patients who respond to the first 4 courses of TEC with a Complete Remission will receive 4 more courses of TEC. Patients who respond to the first 4 courses of TEC with a Partial Remission or Stable Disease will then have their treatment changed to the non-cross resistant NAX regimen.Courses will be repeated every 21 days according to blood counts.A total of 4 courses will be given.</description>
    <arm_group_label>ER- (Triple Neg. and ER- PR+ Her 2 -)</arm_group_label>
    <other_name>Neoadjuvant chemotherapy for breast cancer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab</intervention_name>
    <description>Her-2 positive cases:Patients who respond to 4 courses of TEC with either a partial or complete remission will then receive 4 additional courses of Docetaxel plus Herceptin, and upon completion of the 4th course of DH they will undergo definitive surgery.A total of 4 courses will be given. Courses will be repeated every 21 days according to blood counts. Patients whose response after 4 courses of TEC is either stable disease or progression, will be treated with &quot;NTX&quot;.</description>
    <arm_group_label>Her 2 +</arm_group_label>
    <other_name>Neoadjuvant chemotherapy for breast cancer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab</intervention_name>
    <description>ER+ Cases(ER+PR+Her-2- and ER+PR-Her-2-):After the first course of TEC if the SUV of the primary tumor is &gt;5%, treatment will be TEC x 4 courses. If the Oncotype is low, patients will be switched to hormonal therapy x 6 months. If the Oncotype result is intermediate/high, patients will be NAX chemotherapy x 4 courses. If the SUV post course #1 TEC is &lt;5%, subsequent treatment will depend on the Oncotype.If the Oncotype is low, the treatment will be hormonal therapy x 6 months. If the Oncotype is intermediate/high , the treatment will be NAX chemotherapy x 4. Surgery will be performed 6 weeks after the 4th course of NAX chemotherapy.</description>
    <arm_group_label>ER + (ER+ PR+ Her 2- / ER+ PR- Her 2 -)</arm_group_label>
    <other_name>Neoadjuvant chemotherapy for breast cancer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously untreated (no chemotherapy, hormonal or radiation therapy)invasive breast&#xD;
             cancer.&#xD;
&#xD;
          -  Diagnosis of invasive ductal or lobular breast cancer plus or minus DCIS. Inflammatory&#xD;
             carcinoma will also be elegible.&#xD;
&#xD;
          -  Age≥ 18 years&#xD;
&#xD;
          -  Only female patients are eligible&#xD;
&#xD;
          -  Tumor≥ 1.0cm by MRI and/or sonographic or clinical exam measurements. If the tumor is&#xD;
             &lt;1.0 but the patient has biopsy proven lymph node metastasis, she will also be&#xD;
             considered eligible.Although only tumors≥2cm are consideredmeasurable by RECIST&#xD;
             criteria, we will nevertheless include tumors≥1cm since the primary endpoint is&#xD;
             pathological CR rate.&#xD;
&#xD;
          -  Performance status ECOG≤2 or Karnofsky≥ 50%&#xD;
&#xD;
          -  Peripheral neuropathy≤ grade 1&#xD;
&#xD;
          -  Hematologic (minimal values):Absolute Neutrophil count≥1,500/mm³; Hemoglobin≥8.0g/dl;&#xD;
             Paltelet count≥100,000/mm³&#xD;
&#xD;
          -  Hepatic; Total bilirubin≤ULN AST and ALT and ALP do not have to be within the range.&#xD;
             In determining eligibility the more abnormal of the two values(AST or ALT) should be&#xD;
             use as per protocol table on p.24of 69.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test&#xD;
&#xD;
          -  Men and women of childbearing potential must be willing to consent to use effective&#xD;
             contraception while on treatment and for at least 3 months thereafter.&#xD;
&#xD;
          -  Renal;urine protein:creatinine(UPC)ratio1.0 at screening or urine dipstick for&#xD;
             proteinuria&lt;2+(patients discovered to have˃/=2+ protinuria on dipstick urinalysis at&#xD;
             baseline should undergo a 24 hour urine collection and must demonstrate&lt;/=1g of&#xD;
             protein in 24 hrs to be elegible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast feeding patients are excluded&#xD;
&#xD;
          -  Patients with second malignancies with expected survival&lt;5 years&#xD;
&#xD;
          -  Previous chemotherapy with Taxanes,Anthracyclines or Cyclophosphamide.&#xD;
&#xD;
          -  Patientes with history of severe hypersensitivity reaction to Taxotere(Docetaxel)or&#xD;
             other drugs formulated with polysorbate 80.&#xD;
&#xD;
          -  Pure DCIS diagnoses are not elegible&#xD;
&#xD;
          -  Special histologies with favorable prognosis such as mucinous, tubular are not&#xD;
             elegible&#xD;
&#xD;
          -  Patients with reduced ejection fraction&lt;50% are not eligible&#xD;
&#xD;
          -  Patients with tumors&lt;1.0cm unless biopsy proven axillary node metastasis present.&#xD;
&#xD;
          -  Cardiac thrombotic events in the past 12 months&#xD;
&#xD;
          -  Stroke or transient ischemic attacks (TIA) within 12 months&#xD;
&#xD;
          -  poorly controlled hypertension defined as persistent blood pressure elevation˃150&#xD;
             systolic and/or 100 diastolic not responsive to medications.&#xD;
&#xD;
          -  GI condition that increases risk of perforation within 6 months of study&#xD;
&#xD;
          -  Any serious non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  No minor surgical procedure within 7 days of study entry or major surgery within 28&#xD;
             days of study entry or anticipation of need for major surgical procedure during the&#xD;
             course of the study.&#xD;
&#xD;
          -  Significant vascular disease such as symptomatic peripheral vascular disease.&#xD;
&#xD;
          -  Any evidence of bleeding diathesis or coagulopathy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Cabanillas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auxilio Mutuo Hospital Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando Cabanillas, MD</last_name>
    <phone>787-758-2000</phone>
    <phone_ext>3513</phone_ext>
    <email>fcabanil@mdanderson.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Idalia Liboy, MD</last_name>
    <phone>787-758-2000</phone>
    <phone_ext>3569</phone_ext>
    <email>iliboy@auxiliomutuo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Auxilio Mutuo Cancer Center</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Cabanillas, MD</last_name>
      <phone>787-758-2000</phone>
      <phone_ext>3513</phone_ext>
      <email>fcabanil@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Idalia Liboy, MD</last_name>
      <phone>787-758-2000</phone>
      <phone_ext>3569</phone_ext>
      <email>iliboy@auxiliomutuo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fernando Cabanillas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Auxilio Mutuo Cancer Center</investigator_affiliation>
    <investigator_full_name>Fernando Cabanillas</investigator_full_name>
    <investigator_title>Hematolgist-Oncologist</investigator_title>
  </responsible_party>
  <keyword>NAC Protocol</keyword>
  <keyword>NAC and Oncotype Guided Hormonal therapy for breast cancer</keyword>
  <keyword>Neoadjuvant and Oncotype</keyword>
  <keyword>NAC CCAM 1101</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Lobular</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

